TOP HEADLINES

Featured Story

Analyst casts doubt on Big Data potential of Covance-LabCorp merger

LabCorp closed its $5.7 billion takeover of Covance this week and immediately began talking up the potential for its testing data to turbocharge the CRO's clinical trial business.

Eccrine bags seed funding for Air Force-developed sweat sensor

Eccrine Systems has raised $1.5 million in seed funding to develop a sweat sensor based on know-how that originated at the University of Cincinnati and the Air Force Research Labs. The Cincinnati, Ohio-based startup will use the cash to forge ahead with the development of wearable sensor technology it plans to pitch to clinical trial sponsors.

Novo Nordisk set to rake in up to $335M from IT unit IPO

Novo Nordisk has set the terms for the IPO of its IT services unit NNIT. If NNIT prices at the top end of its range when it goes public in the next week or so, the listing could generate up to $335 million for Novo Nordisk.

H3 hooks up with Foundation Medicine for data-driven oncology R&D

Foundation Medicine has followed up its transformational deal with Roche by inking an oncology alliance with Eisai-backed H3 Biomedicine. The deal sees Foundation Medicine pair its genomic database with H3's computational biology capabilities.

Big Data digging yields unprecedented road map of the epigenome

A massive data generation and analysis program has uncovered a map of the epigenome, the switches that turn genes off and on. Researchers published their findings in a series of papers in Nature and released the data for further analysis through the National Center for Biotechnology Information.

MORE NEWS

From Our Sister Sites

FierceAnimalHealth

Petaluma, CA-based Oculus Innovative Sciences announced Thursday that it has launched an animal health unit and 6 new products for the treatment of wounds, skin and eyes.

FierceMedicalDevices

St. Jude Medical agreed to pay as much as $14.25 million to settle about 950 claims related to its Riata defibrillator leads. The wires used to shock a heart that is beating abnormally degraded in as few as four years and were pulled from the market in 2010.